Initial therapy, persistence and regimen change in a cohort of newly treated type 2 diabetes patients

British Journal of Clinical Pharmacology

Volumn 79, Issue 6, 2015, Pages 1000-1009

  Grimes, Ronan T ^a   Bennett, Kathleen ^a   Tilson, Lesley ^b   Usher, Cara ^b   Smith, Susan M ^c   Henman, Martin C ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

^c ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

real world treatment patterns; treatment progression; type 2 diabetes mellitus

Indexed keywords

METFORMIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DRUG UTILIZATION; FEMALE; HUMAN; IRELAND; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; TIME TO TREATMENT; VERY ELDERLY; AGE; BLOOD; CLINICAL PRACTICE; COMBINATION DRUG THERAPY; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG DATABASE; DRUG SUBSTITUTION; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODEL; PROTOCOL COMPLIANCE; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COMORBIDITY; DATABASES, PHARMACEUTICAL; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPOGLYCEMIC AGENTS; IRELAND; LOGISTIC MODELS; MALE; METFORMIN; MIDDLE AGED; ODDS RATIO; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SULFONYLUREA COMPOUNDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84929989905     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12573     Document Type: Article

References (40)

1. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM, Platt R,. Discontinuation of antihyperlipidemic drugs-do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995; 332: 1125-1131.
2. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR, American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
3. Filion KB, Joseph L,. Trends in the prescription of anti-diabetic medications in the United Kingdom?: a population-based analysis. Pharmacoepidemiol Drug Saf 2009; 18: 973-976.
4. Baviera M, Monesi L, Marzona I, Avanzini F, Monesi G, Nobili A, Tettamanti M, Riva E, Cortesi L, Bortolotti A, Fortino I, Merlino L, Fontana G, Roncagliono MC,. Trends in drug prescriptions to diabetic patients from 2000 to 2008 in Italy's Lombardy Region: a large population-based study. Diabetes Res Clin Pract 2011; 93: 123-130.
5. Mazzaglia G, Yurgin N, Boye KS, Trifirò G, Cottrell S, Allen E, Filippi A, Medea G, Cricelli C,. Prevalence and antihyperglycemic prescribing trends for patients with type 2 diabetes in Italy: a 4-year retrospective study from national primary care data. Pharmacol Res 2008; 57: 358-363.
6. Boyc KS, Yurgin N, Lage MJ,. Trends in the prescription of antidiabetic medications in France: evidence from primary care physicians. Adv Ther 2007; 24: 803-813.
7. Zaharan NL, Williams D, Bennett K,. Prescribing of antidiabetic therapies in Ireland: 10-year trends 2003-2012. Ir J Med Sci 2013; 183: 11-18.
8. Harkins V,. A Practical Guide to Integrated Type 2 Diabetes Care. Edited by Irish College of General Practitioners, Health Service Executive, Irish Endocrine Society. Dublin: Health Service Executive, 2008.
9. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
10. Holman RR, Sourij H, Califf RM,. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014; 383: 2008-2017.
11. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F,. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
12. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT,. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
13. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
14. Kishore P, Kim SH, Crandall JP,. Glycemic control and cardiovascular disease: what's a doctor to do? Curr Diab Rep 2012; 12: 255-264.
15. Brouwer E, West S,. Initial and subsequent therapy for newly diagnosed type 2 diabetes patients treated in primary care using data from a vendor based electronic health record. Pharmacoepidemiol Drug Saf 2012; 21: 920-928.
16. Desai NR, Shrank WH, Fischer M, Avorn J, Liberman JN, Schneeweiss S, Pakes J, Brennan TA, Choudhry NK,. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med 2012; 125: 302.e1-3027.
17. Lamberts EJF, Nijpels G, Welschen LMC, Hugtenburg JG, Dekker JM, Souverein PC, Bouvy ML,. Long term patterns of use after initiation of oral antidiabetic drug therapy. Pharmacoepidemiol Drug Saf 2011; 20: 351-358.
18. Boccuzzi SJ, Wogen J, Fox J, Sung JCY, Shah AB, Kim J,. Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care 2001; 24: 1411-1415.
19. Health Service Executive Primary Care Reimbursement. Statistical Analysis of Claims and Payments 2012. Dublin: Health Service Executive, 2012.
20. Lord JM, Flight IHK, Norman RJ,. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003; 327: 951-953.
21. Grégoire J-P, Sirois C, Blanc G, Poirier P, Moisan J,. Persistence patterns with oral antidiabetes drug treatment in newly treated patients-a population-based study. Value Health 2010; 13: 820-828.
22. Shorr RI, Ray WA, Daugherty JR, Griffin MR,. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 1996; 44: 751-755.
23. National Institute for Health and Care Excellence. Type 2 Diabetes-Newer Agents (Partial Update of CG66) (CG87). London: National Institute for Health and Care Excellence, 2009; Available at http://guidance.nice.org.uk/cg87 (last accessed 8 July 2014).
24. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM,. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 2008; 62: 76-87.
25. O'Shea MP, Teeling M, Bennett K,. An observational study examining the effect of comorbidity on the rates of persistence and adherence to newly initiated oral anti-hyperglycaemic agents. Pharmacoepidemiol Drug Saf 2013; 22: 1336-1344.
26. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH,. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421-431.
27. Beest FJAP, Bij S, Erkens JA, Kessabi S, Groot M, Herings RMC,. Effect of non-persistent use of oral glucose-lowering drugs on HbA1c goal attainment. Curr Med Res Opin 2008; 24: 2523-2529.
28. McCrimmon RJ, Ryan CM, Frier BM,. Diabetes and cognitive dysfunction. Lancet 2012; 379: 2291-2299.
29. Holstein A, Stumvoll M,. Contraindications can damage your health-is metformin a case in point? Diabetologia 2005; 48: 2454-2459.
30. Shaw JS, Wilmot RL, Kilpatrick ES,. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med 2007; 24: 1160-1163.
31. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS,. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1-12.
32. Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C,. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care 2005; 28: 600-606.
33. Peyrot M, Rubin RR, Siminerio LM,. Resistance to insulin therapy among patients and providers: results of the cross-national diabetes attitudes, wishes, and needs (DAWN) study. Diabetes Care 2005; 28: 2673-2679.
34. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G, ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
35. Huxley R, Barzi F, Woodward M,. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006; 332: 73-78.
36. Peters SAE, Huxley RR, Woodward M,. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet 2014; 383: 1973-1980.
37. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O,. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
38. Lily M, Godwin M,. Treating prediabetes with metformin: systematic review and meta-analysis. Can Fam Physician 2009; 55: 363-369.
39. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
40. Rhee MK, Herrick K, Ziemer DC, Vaccarino V, Weintraub WS, Narayan KMV, Kolm P, Twombly JG, Phillips LS,. Many Americans have pre-diabetes and should be considered for metformin therapy. Diabetes Care 2010; 33: 49-54.